ZYLOX-TONBRDG.MED.TECH.H1 Defensive Interval Ratio
ZYLOX-TONBRDG.MED.TECH.H1 defensive interval ratio. ZYLOX-TONBRDG.MED.TECH.H1 (818) has a Defensive Interval Ratio of 1302 days as of June 2025. Defensive assets of €1.15 Billion (cash €-, short-term investments €1.15 Billion, receivables €2.38 Million) cover 1302 days of daily cash needs of €885.01K/day. See 818 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Defensive Interval Ratio of ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
Defensive interval ratio of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024. This chart shows how ZYLOX-TONBRDG.MED.TECH.H1's Defensive Interval Ratio has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 1302 days, meaning defensive assets of €1.15 Billion can fund 1302 days of operations without new revenue. Check ZYLOX-TONBRDG.MED.TECH.H1 (818) asset resilience to evaluate the company's liquid asset resilience ratio.
ZYLOX-TONBRDG.MED.TECH.H1 Defensive Interval Ratio by Year (2021–2024)
ZYLOX-TONBRDG.MED.TECH.H1 defensive interval ratio by year from 2021 to 2024. The table below presents the year-by-year Defensive Interval Ratio for ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024, covering 4 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For the complete balance sheet picture, see ZYLOX-TONBRDG.MED.TECH.H1 balance sheet assets.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2024 | 946 days | €866.32 Million | €915.53K/day | €- | €864.78 Million | ▲ +458 days |
| 2023 | 489 days | €425.47 Million | €870.64K/day | €- | €424.29 Million | ▼ -1087 days |
| 2022 | 1575 days | €656.38 Million | €416.67K/day | €- | €655.37 Million | ▼ -4104 days |
| 2021 | 5680 days | €1.51 Billion | €266.04K/day | €- | €1.51 Billion | — |